News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BMG Pharma S.r.l. and Luqa Pharmaceuticals Announce Long-Term Partnership for the Registration and Commercialization of BMG Pharma products in China and Hong Kong


7/12/2013 9:48:22 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MILAN,Italy and SHANGHAI, July 12, 2013 /PRNewswire/ --

BMG Pharma S.r.l and Luqa Pharmaceuticals are pleased to announce a long-term partnership for the commercialization of BMG's products in China and Hong Kong. Under the terms of this agreement, Luqa will exclusively register and commercialize BMG's highly innovative dermatology, oral care and Cancer Support Therapy products.

The agreement will enable Luqa to rapidly expand its dermatology offering and enter the attractive oral care and supportive care market of China, fast growing and largely self-payment driven categories. The partnership covers IaluXid, a unique, non-antibiotic, combination gel formulation treating skin infections;,GelX and GelX Xero, innovations in supportive care preventing and treating Oral Mucositis and Xerostomia; and Aftacure, treating aphthous ulcers and mouth lesions.. These products have been developed to address major unmet needs for patients and physicians in the evolving China market. Luqa expects to launch this family of products directly from late 2015 onwards.

"We are pleased to enter into a partnership with Luqa Pharmaceuticals, a company with whom we share the vision and values. BMG's proven innovation capabilities complements Luqa's deep understanding of the evolving needs in China's healthcare market", said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l. "This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world."

"We are happy to have entered into this alliance with BMG Pharma S.r.l..", said Robert Braithwaite, CEO of Luqa Pharmaceuticals. "We are excited to further expand into the fast growing and largely self pay areas of dermatology oral care and Cancer Support Therapy segments. This partnership with BMG is in line with our strategy to build a portfolio of innovative and high-growth potential products through targeted partnerships. BMG Pharma's products complement our portfolio of innovative therapies, and we look forward to develop them into leading healthcare brands. We plan to work closely with BMG on a relationship that will contribute to the continued and sustainable growth of our company."

About BMG Pharma S.r.l

BMG Pharma S.r.l. is an Italian Specialty Pharmaceutical Company leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology, gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES